Big pharma, Partnering, Pharma

Advaxis pharma partners with Merck & Co. for cancer trials

Posted on 26 August 2014

Tags: , , ,

Advaxis pharma partners with Merck& Co. for a clinical trial collaboration agreement.

Advaxis is developing and hoping to commercialize cancer immunotherapies based on a propriety platform that uses engineered Listeria monocytogenes to redirect the immune system to kill caner.

The planned Phase I/II clinical trial will evaluate the safety and efficacy of Advaxis’ ADXS-PSA as a standalone treatment and also in combination with Merck’s pembrolizumab, an injectable monoclonal antibody, in patients with previously treated metastatic prostate cancer.

For further deal information visit Current Agreements (subscription required)

Related

Report: Oncology Partnering Terns and Agreements

Report: Partnering Agreements with Merck & Co. 2009-2014

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply